Denosumab is the generic name for brand name Prolia® and Xgeva® manufactured by Amgen. No generic version is available for this medicine.

Prolia is 60 mg of denosumab administered under the skin twice a year – every 6 months. Prolia is indicated for postmenopausal women or men at high risk for fracture. Also it is approved for use in women with breast cancer or men with prostate who have not had spread of their cancer and are taking medicines that accelerate bone loss. Refer to Prolia for further information.

Xgeva is 120 mg of denosumab administered under the skin every 4 weeks. It is indicated for individuals with solids tumors like breast and prostate cancer that has spread to the bone (metastases) to prevent further complications in the bone.

Other resources:

Prolia product website

Xgeva product website